Vimarsana
Biggest News Aggregation in the World

Primary Peritoneal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Peritoneal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Peritoneal Today - Breaking & Trending Today

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer - Vimarsana News

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Published: June 4, 2023

Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy Clinically... | June 4, 2023

Source: marketscreener.com
Related Topics:
United StatesUniversity Of OklahomaDavid OmalleyKathleen MoorePivekimab SunirineMirvetuximab SoravtansineSarah Cannon Phasei ProgramJames Cancer CenterUniversity Of Texas Md Anderson Cancer CenterAmerican Society Of Clinical OncologyImmunogen IncClinical ResearchOhio State UniversityDepartment Of LeukemiaClinical OncologyAnnual MeetingAssociate DirectorGynecologic OncologyInitial ReportAdvanced High Grade Epithelial OvarianPrimary PeritonealFallopian Tube CancersHigh Folate Receptor Alpha ExpressionLate Breaking Abstract SessionPlatinum Sensitive Ovarian
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting - Vimarsana News

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Published: May 9, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--May 9, 2023--

Source: wsiltv.com
Related Topics:
University Of OklahomaUnited StatesKathleen MooreAnna BerkenblitCourtney OkonekRobert StanislaroDavid OmalleyMirvetuximab SoravtansinePivekimab SunirineAnabel ChanClinical ResearchExchange CommissionDepartment Of LeukemiaImmunogen IncJames Cancer CenterAmerican Society Of Clinical OncologyCompany Quarterly Report On FormOhio State UniversityExchange Commision OnCompany Annual Report On FormSarah Cannon Phasei ProgramExchange Commission OnUniversity Of Texas Md Anderson Cancer CenterClinical OncologyAnnual Meeting
Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers. - Vimarsana News

Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

Published: June 24, 2022

/PRNewswire/ -- Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The...

Source: prnewswire.com
Related Topics:
United StatesGreenfire BioZhen LuRobert BastSteve MorrisBajit GillWorld Cancer Research Fund InternationalUniversity Of Texas Md Anderson Cancer CenterAmerican Cancer SocietyCancer CenterScientific Advisory BoardClinical InvestigationAmerican CancerWorld Cancer Research FundClinical StudyRecurrent OvarianPrimary PeritonealFallopian Tube Cancers
OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer - Vimarsana News

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer

Published: April 21, 2022

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
Ashleyr RobinsonKathleen MooreLaura BenjaminUniversity Of OklahomaLifesci PartnersDrug AdministrationOncxerna Therapeutics IncXerna TherapeuticsNavicixizumab Plus PaclitaxelPatients With Platinum Resistant OvarianPrimary PeritonealFallopian Tube CancerClinical OncologyChief Executive OfficerOncxerna TherapeuticsFast TrackMedia ContactSci PartnersNcxerna Therapeutics Announces Journal Of Clinical Oncology Publication Featuring Phase 1b Data Navicixizumab Plus Paclitaxel In Ovarian Cancer